 | Gursel Aktan |
Prominent publications by Gursel Aktan
BACKGROUND: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer.
METHODS: In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated ...
| Also Ranks for: Chemotherapy Patients | metastatic triple | negative breast | progressionfree survival | addition pembrolizumab |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
[ PUBLICATION ]
BACKGROUND: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.
METHODS: In this parallel groups, randomised, open-label, phase 3 study undertaken between Jan 5, 2008, and May 27, 2010, women from 23 countries with HER2-positive ...
| Also Ranks for: Lapatinib Trastuzumab | phase 3 trial | breast cancer | humanized antineoplastic | neoplasms chemotherapy |
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is ...
| Also Ranks for: Negative Breast | pembrolizumab patients | early triple | definitive surgery | pathological complete response |
PURPOSE: Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here.
PATIENTS AND METHODS: Patients with HER2-positive MBC whose ...
| Also Ranks for: Survival Benefit | lapatinib trastuzumab | positive metastatic | growth factor | human epidermal |
Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of ...
| Also Ranks for: Neoadjuvant Lapatinib | fdg pet | early prediction | trastuzumab combination | primary tumors |
AIM: To present the impact of treatments on health-related quality of life (HRQoL) from the double-blind, randomised phase III COMBI-d study that investigated the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600E/K-mutant metastatic melanoma. COMBI-d showed significantly prolonged progression-free survival for the combination.
METHODS: HRQoL was evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life ...
| Also Ranks for: Life Impact | dabrafenib monotherapy | combination treatment | metastatic melanoma | phase iii |
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
[ PUBLICATION ]
BACKGROUND: Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab-the standard adjuvant treatment. We investigated the efficacy and safety of adjuvant lapatinib for patients with trastuzumab-naive HER2-positive early-stage breast cancer, started at any time after diagnosis.
METHODS: This study was a placebo-controlled, multicentre, randomised phase 3 trial. Women outpatients from 405 [corrected] centres in 33 countries [corrected] with ...
| Also Ranks for: Positive Breast | 3 trial | adjuvant lapatinib | diseasefree survival | antibodies monoclonal |
PurposeTo identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Patients and methodsEligibility criteria were advanced solid tumors, 18 years or older, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Exclusion criteria included Type 1 diabetes, active GI disease, leptomeningeal disease, or current evidence/risk of retinal venous occlusion/central serous retinopathy. ...
| Also Ranks for: Multiple Myeloma | solid tumors | mek inhibitor trametinib | inhibitor afuresertib | response relationship |
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
[ PUBLICATION ]
PURPOSE: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC.
METHODS: KEYNOTE-012 (ClinicalTrials.gov identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent ...
| Also Ranks for: Advanced Triple | antitumor activity | negative breast | patients tnbc | tumor cells |
BACKGROUND: Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management.
PATIENTS AND METHODS: All patients on the BRF133220 phase I/II trial of CombiDT treated at the standard dose (150/2) were included for assessment of pyrexia (n = 201). BRAF and MEK inhibitor-naïve patients (n = 117) were included for efficacy analyses. Pyrexia was defined as temperature ≥38°C ...
| Also Ranks for: Pyrexia Patients | clinical trial | metastatic melanoma | trametinib therapy | median duration |
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
[ PUBLICATION ]
BACKGROUND: Pathologic complete response (pCR) is a common efficacy endpoint in neoadjuvant therapy trials for triple-negative breast cancer (TNBC). Previous studies have shown that pCR is strongly associated with improved long-term survival outcomes, including event-free survival (EFS) and overall survival (OS). However, the trial-level associations between treatment effect on pCR and long-term survival outcomes are not well established. This study sought to evaluate these associations ...
| Also Ranks for: Survival Outcomes | pathologic complete response | pcr efs | negative breast | sensitivity analyses |
BackgroundMetastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for this breast cancer subtype. Instead, chemotherapies approved for metastatic breast cancer (MBC) are used for mTNBC (National Comprehensive Cancer Network Guidelines [NCCN] v1.2019). Atezolizumab in combination with nab-paclitaxel was recently approved for programmed ...
| Also Ranks for: Breast Cancer | metastatic triple | patients mtnbc | phase iii trials | treatment landscape |
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
[ PUBLICATION ]
Pathologic complete response (pCR) following neoadjuvant therapy has been associated with improved event-free survival (EFS) and overall survival (OS) in early-stage breast cancer. The magnitude of this association varies by breast cancer subtype, yet further research focusing on subtype-specific populations is limited. Here we provide an updated and comprehensive evaluation of the association between pCR and survival outcomes in triple-negative breast cancer (TNBC). A literature review ...
| Also Ranks for: Complete Response | survival outcomes | breast cancer | neoadjuvant therapy | patients tnbc |
Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib
[ PUBLICATION ]
The induction of CYP2C9 by dabrafenib using S-warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib pharmacokinetics were evaluated in patients with BRAF V600 mutation-positive tumors. Dabrafenib single- and repeat-dose pharmacokinetics were also evaluated. S-warfarin AUC(0- ∞) decreased 37% and Cmax increased 18% with dabrafenib. Dabrafenib AUC(0- τ) and C(max) increased 71% and 33%, respectively, with ketoconazole. ...
| Also Ranks for: Braf Inhibitor | cytochrome p450 | drug interaction potential | systemic exposure | humans imidazoles |
Gursel Aktan: Influence Statistics
| Concept | World rank |
|---|---|
| stratum 95 | #3 |
| 95 stratum | #3 |
| intravenous pembrolizumab day | #3 |
| chemotherapy mtnbc | #3 |
| neoadjuvant therapy tnbc | #3 |
| day intravenous pembrolizumab | #3 |
| potential mtnbc treatment | #3 |
| adjuvant lapatinib patients | #3 |
| activity mtnbc | #3 |
| firstline laterline settings | #3 |
| lapatinib clinical | #3 |
| patients intravenous eribulin | #3 |
| nct02819518 | #3 |
| eribulin pembrolizumab | #4 |
| suvmax reductions baseline | #5 |
| suvmax reductions | #5 |
| weeks metabolic responses | #5 |
| baseline metabolic response | #5 |
| approved breast | #5 |
| suvmax reductions pcr | #5 |
| placebochemotherapy | #5 |
| stratum 2 | #5 |
| pcr neoadjuvant trastuzumab | #5 |
| adjuvant lapatinib women | #5 |
| phase keynote173 | #5 |
| metabolic responses week | #5 |
| approved metastatic | #6 |
| pcr neoadjuvant lapatinib | #6 |
| approval median | #6 |
| diseasefree survival lapatinib | #6 |
| neo altto | #6 |
| study 3 trial | #6 |
| trastuzumab daily lapatinib | #6 |
| tis ypn0 | #6 |
| intravenous eribulin | #7 |
| keynote173 | #7 |
| adjuvant lapatinib | #7 |
| enhance 1 | #7 |
| lapatinib lymph | #7 |
| tnbc efs | #7 |
| efs tnbc | #7 |
| 1 stratum | #8 |
Key People For Breast Cancer
Gursel Aktan:Expert Impact
Concepts for whichGursel Aktanhas direct influence:Breast cancer, Adjuvant lapatinib, Neoadjuvant lapatinib, Negative breast, Dabrafenib monotherapy, Pembrolizumab patients, Metastatic triple, Phase iii.
Gursel Aktan:KOL impact
Concepts related to the work of other authors for whichfor which Gursel Aktan has influence:Breast cancer, Neoadjuvant chemotherapy, Immune checkpoint inhibitors, Triple negative, Tumor microenvironment, Pathological complete response.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |